Category : Seeking Alpha

Boston Beer Company Names Phil Hodges Chief Operating Officer

Founder, Brewer and Chairman of the Board Jim Koch to Continue as CEO Founder, Brewer and Chairman of the Board Jim Koch to Continue as CEO

Getty Images Announces Final Results of Exchange Offer and Consent Solicitation

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Getty Images Holdings, Inc. (NYSE: GETY) (“Getty Images”) announced today the final results of the previously announced offer by Getty Images, Inc. (the “Issuer”), an indirect wholly owned subsidiary of...

Fabrinet to Announce First Quarter Fiscal Year 2026 Financial Results on November 3, 2025

BANGKOK, Thailand, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of comple...

Triller Group Receives Nasdaq Delisting Determination Letter for Non-Compliance with Listing Rule 5250(c)(1) and Intends to Request a Hearing before Nasdaq Hearings Panel

Los Angeles, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Triller Group Inc. (“Triller”, “Triller Group” or “the Company”) today announced that on October 14, 2025, it received a delisting determination letter from the Listing Qualifications Staff of the Nas...

Cheer Holding Receives Nasdaq Notification of Non-Compliance with Listing Rules 5550(a)(2)

BEIJING, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced that on October 16, 2025, it rece...

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

AFFIRM-1 trial did not meet primary endpoint or secondary endpoints

SINTX Technologies 的 SINAPTIC® 足踝植入系统获得 FDA 上市许可

获 FDA 批准且在美国本土制造的植入系统，为 SINTX 进军规模达数十亿美元的美国市场奠定了基础

SINTX Technologies 獲 FDA 批准 SINAPTIC® 足踝植入系統

ה-FDA אישר ומערכת שתלים מתוצרת ארה"ב- ממצבת את SINTX בכניסה לשוק האמריקני של מיליארד דולר

La FDA autorise le système d’implant de pied et de cheville SINAPTIC® de SINTX Technologies

Fabriqué aux États-Unis et désormais approuvé par la FDA, ce système d’implant conçu par SINTX s’ouvre les portes d’un marché américain valorisé à plusieurs milliards de dollars

SINTX Technologies erhält FDA-Zulassung für SINAPTIC® Fuß- und Sprunggelenk-Implantatsystem

Das von der FDA zugelassene und in den USA hergestellte Implantatsystem positioniert SINTX für den Eintritt in den milliardenschweren US-Markt

SINTX Technologies Mendapatkan Persetujuan dari FDA untuk Sistem Implan Kaki dan Pergelangan Kaki SINAPTIC®

Sistem implan yang disetujui FDA dan diproduksi di AS menempatkan SINTX untuk memasuki pasar AS senilai miliaran dolar

シントクス・テクノロジーズ (SINTX Technologies)、SINAPTIC®足・足首用インプラントシステムでFDA認可を取得

FDA認可を受け、米国内で製造された本インプラントシステムにより、シントクスは数十億ドル規模の米国市場への参入を実現

SINTX 테크놀로지스, SINAPTIC® 발·발목 임플란트 시스템에 대해 FDA 승인 획득

미국 FDA 승인 및 현지 제조 기반 임플란트 시스템으로, SINTX는 수십억 달러 규모의 미국 시장 진입 본격화

SINTX Technologies Menerima Kelulusan FDA untuk SINAPTIC® Foot & Ankle Implant System

Sistem implan yang diluluskan oleh FDA dan dikilangkan di Amerika Syarikat membuka peluang bagi SINTX untuk menembusi pasaran bernilai berbilion dolar negara itu

SINTX Technologies Recebe Autorização da FDA para Sistema de Implantes de Pé e Tornozelo SINAPTIC®

A FDA liberou o sistema de implante fabricado nos EUA, posicionando a SINTX para entrar no mercado bilionário do país